lilly retatrutide Eli Phase 3 obesity trial results 2026 retatrutide #elililly #retatrutide #weightloss #obesitycare

Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice

The boxed warning exists as a precaution based on animal data, not because humans have actually developed these tumors from the medication

Most people notice visible changes within four to six weeks of starting GLP-1 therapy

Both compounds cause primarily gastrointestinal side effects that peak during dose escalation

Non-hypothalamic regions A variety of non-hypothalamic regions are also studied for the neural circuitry targets of GLP-1RA actions

Ongoing studies explore the potential of CV, renal and neuroprotective benefits of GLP-1RAs and the potential of using GLP-1RAs for other indications, including NASH, neurodegenerative diseases, and T1D